y_80?mBLʴtbڧ@vIl'6ے@y!H::::뛷|ot(=YA(}N$ĝLauY$3/( d$e?uu9fG7G< fa·t'N*7nS?X>e2E+?AW \}7]ħ/c5&nHgnPcbDn,uiv787MЛ{WaAWzh|1묛_5ۼ,7C;]Y~ਫ਼uz-hl㤛}= I4 -ڍn֙Im{b|xzՋyy ӻW!x+m?~HWj䨧Y?׺PMvl{_z39"sW7if mh"iߣݰu~ލga4it fio0m| a_ot˶Z؄U7gz/O#L7*<<U,Ӳ_i{;18n>N[qp{^8# <'LC;i @5^w5Cq3XӅQ,`'Oa޳MURUE ᦖzZT)zz3<@ʀ+uQkU1D'8_g:OWmFOUbpXtwN6 xND "i-ﻳjF>] _+v/Cd얃)~/o[F6NԃD_$sq 4T/{ćspz,HAk`[)Xgs|=kV=9b4-OuМ'Y *?'5'?}\M~^~>^^էWP`ӣoGm^4<^OѧOWw^}j|>|?|8=l4@鳛_߿:Fف"d_V#0 /F#ԋ!R`uMF׽tc.9^Lp+X&3n `d{^ݾ4y޼hܾnqCOX_TWfϧ>_gW/ێk¹ۿ{qfΐ8Kܻ]ptLvDd=%hL7 Z9إx ]xcRQ<~ U7j8"KUy Qhwz9u,O[f0eyNz>@1Q/q鍝Ah#/O[xo >́BGs h>aw7RUp|3r ):h^޾rWcuj0d7K^`г=q7w—Ij5vzz?DDyp;T*^|Po>×.n0Ӌdp}mw>\ ^n@&&$pdC9Jvv:JkJN^oZSi1lޟ緯F})-h5gˣ*< [nޟۣgCut,ޢl7@gHTq}q1r_l/Z5_*Ŵl[w[%$قilsQgaYz}U|ܟtEa݄-6SRGԿ>[2Vy3w8T;Ço㛳侉bwspc\|!wԆSu]l7"=?O[`.d>6>}ξ_[׃eOB t<\܁!>?L hݱ3CrL[#Oun8y@oO%@!mM%@;C˻![)-؍5 5h?mmo/a jӰ'H?S?bƛOdvZ "`{|ZSx߾ܢ! |B]S|{5$hy^ma+OGx ]Cp\cy)3(uAD]LZWU )m"= G3?̈is(]890-Ru'E)wj [^)g+DUN!D";Z}uVBVQ%O#XSHGd ,J+c&U<`J)d rBIA0:ZZE<%[1׾1)6~l7Ҥun1rZ^.-v e.3F1,HhzpTο}Ro!B!#@,wp)+[/wMGs]mփޠ"{ϿAvh]zsB6ltAlN_[GLJޛz1G${>oݲ&jESyM,GŁ7ݿQ{p`r¥zAUї7^LQ} M/Öu`E> d~hb`⟥M ѿ ߫աG(Wr>S͏N|Kwo~OW~G yܛ^kIz\Wgei" 0Φy8Pxe!ӿ >r/O%S"ʑkI}0$8U{ί~#y_7H464_o/lUa.Bxhr ,#.`s2"@ ;dpo"tDB̍e[;| og?rF?~p:/"POFq'do_!,Ӌo0f2Hh8dmƓ.b/?_.>&J/#׫!ݥ~+$ #;=dVDQ:wj!XsC|zU^{+}A;L4<&X rnGx ԽQ\m DB(Gp)2B'D` +`Eh2S5@ $ʗBڼ]f`ТcK;t{;@ůؙ<2HZ,1(X~߾ղataP=p_dJ "(waAW5UDJmDKH3 !S(tNnDeKԺts|.Tp޼kK] fzR26AZoTۥ+(P]g!Vh8,T&2H41-;䓫@uJ"(4Y"׋LEVI<+^H˳}}M}:OrQk.e_m1yȋQ0+Zֳ~#PQb_>Wfw;8Z \>L׌cߑvCOA0.MkNwvwp^din`cn3~{@A<<~3/>h";ez;q0dewKVbyЉt1Y4n5.Dۂw1yp^Xm&$~1%#Ge}{;1 >~lL~U bPvTv8q1nƗ1\|K?]]4/goo^qpl?~ǩ{{wݾ}5?xws_}qm0lWۋ yS~sKkS~1/A<9]n_-^Gj_fo/OͷzyvpJMj?&TS=oo_OE Q7bc^<]H?$?o_p\wvm\K5c.I־?2MFw6< }S η׬ݔ.G`?n5>* .M!pؙ^\tnmվm>/6Ҍ>AqTß~9Ylmkᓷo϶7ߖcWϷۇwmlH٧oڬםۑ_zpexN^Ƣqӻw4<~+ F|n>pZ=}y,q}:X^_oη{ip51@tWF|?_2:mޚ{\w||NF|x{7:@䫱_;}?|i>{u|u4ikAGpuy>FtPS_ﷇ?a}g>׼4foFPSeOS?u|x9yuzc}o_mL_<4 ; ozp|ܞl@X_HwyH!=<{QI?ڵ''3~}xvspl;ip׌tW6}k{K|{C\V? ?޾LhponϽ7}!xxp4m^nxr?u^_<_~y}go}l]~noO'߾w1^|~ټ1_߽tϫw7_/QHg?O#BWaL>}v.no?4߿ťw]|pxL_'G|t~239_wY7NRhEyp28h=k|wο؋{ʗ_}u0 OwשQWft^uCӧoo3ř?ߏmt9{Nwξ]: N/7adv+I&<:o\%>ޝݷƇo-A̩i:_| $|}i{_^z}]:TpԇC'so{؎ߙO=ܽ w߃_k\_pniK8͋ӷG/ywq޼zVut޿͎ճwҷ />4GOQ:7^}[BK^4ۻZ|~;R_;/'Io$>ۜ}|z ՗އ%uQ27kO +/>|3^iTJdzAc[w0H>W׃ Qw~0epuvxx~|4ۛw};pZ ˯óai%R)x}R%`E^5lh7?Ķ d/ :`A:W/'=LLg7NdL8)VGn]",얚wfhUvas]_}.y%'}UN5> e^Us0b yPbJ-ׯo/ ڞ}{,ooorT1%y`\hJ`4jx'e5ɯ^$;x&t Xڶp/q8bd3]4yK壜3S]4Dd9]9̜V`8L "wR< .7gJMl}rl?޶\KXowAN.pK&< *o9y;M/,\`ULZ*UB"ޔg}YH\el2G Ɉ53 [7+Px)ࣰ>Ws׋,3Xl&\:ſn{pq&'܈_Q]}b{ >EzZi+??TM*eNSlswAޱ+طw& Lr8P\3ߊȧt2KwQ|y7 {z?~ޛw%g::h@gw)t^=&[~_Ƥ0N~Gһڥ͆H*œ I)tWf{:$X%2+,{A7p{`+/jVm0I&AP8_u?QWIK"KX_zphp{!iSi/66W747}/qCչss$P뵤UsFwUt|RoNN$vojޏDBQGAX1:MMJV1gԠzV, =W?M;j83cT}g5{{%Ff zۉeo٪ zaw(<ɢיOMEm9eò&ivo1)̻ZG2_[5_QKOf0N"Mh(VW^搪 I BwPg'Un4$iII{ 4h5qyN& S/f+Xi#|;eޘ1T{Z gѴ;ȏ^XshG܍aw &C괾{EF]?J#;ƺS68G;n.]QHmdkgY:|o"_^4f*jz4 peo~KoR߿;.|WZ hIҫׯ5 ޝg=vӀQ͝W4qfic {rka*tR-Iu,l-K9evMY{/PuM@yQhT[3y1V}c`iC/ci0H;Ad8zV6 mV@\g#+|R,D,J=+P{o9Dy0)`h J>N ͣ`IvXK&'(e4U۶L4,\?뙾uFZ-,cXM%Ղͼ ˠN{ןf0wC;3S?\ e "ˤ4D>_.@;c8M](H<݄e:eۃ!Ī/8nҚK~sXF(Z~_,kckM«OWwATSƉ $^ڦ$'1n*N6["&ݬOBG.9-:%r횛Buu1ݕ:Жrϭ7 kXLfV6މڮ ^w͞;bX`bހ4 F?eQOrjM95֒3z6]rUXYE2cyK+{̍h؞3>@ף~>,MIV2X9K&v*!{ zͳd[߬gFb#+ e mljL`]@e$؍ߧ_;?|BIqʪ`5w |ɔXW1Ĭz5˫ !v-,dkXc%@q6]̽\o8 7@ '`k/;*u R%/[m$n&ĿC~ݤFWu84PFuT Sʄw?өO2̼6$?='?S^żIW` COP*/IA(G\!Zx(hj!;`M gekaMtd [I Uȟ`q~Ӌ?iTu DE\$r`rkѺTSж\mhDY`)+!¾;/ٺۛm#7lM{U+pp0v68mI2M]#P0ó"`^a&]=pRhj¿KEG;fr ѭ6'h?^S5Wvo`,azBiZzab>!Zw,";ail>u 1T(V "QCPyw!,xاγUiP`7^#nU`vaydK1W!g3""Gs3%|D!&° {dt"R$2?Hg"UhKWQȒ  +kUD)"ĬT P rUWIh=Au o0f"w ȍ0XSZE+*8رrVc9b6UX0X.܍U1t+'Q=0yBCm)R¹Y !Qiy˅sϝ A)sJB0n;0RQTN 0nFeYoleSآ(2oꝺ*jUeO(vVa ,"5ta8^_ \pRY4&z/ YF+d \ l~UA`o DZu]-Hߵrjv& 񴓢ЁQH,bo CD{"*C⧜NaW)N;[+jUK]32W);JMMAk,%W( IS~\!}h6Wn.axpXyܥ*2stt0X`f ayq3Kw*:cGN德JtyQp A8lt ke*X x;3^Nݣ؍c+RPMxm j♱4%-\F-nNԱrjO.*&ln2!PnߝFÁtfgޠ~='zDAF;4ǹTNMM"HEN '.Z'i `x&*=n6e8ȁMR ,-8l=u?pׅn؂4[+c9D&Ghj:6qF])/a쫇WXT K]8]̜`k 0Ǜ3ò63vp& QVeZ0 p"ڵM,R.tu.6y섮д R] 7ҹogx~vj4r5懗AܙRviu\aQ%Nk( Lƻ5_[ơ=G'T1yB.?'AuI3gcm|j˩NL%#U4*5)oSZNuJ+\/p GOVc, }z oI\dMGj:K@-.bhNt#m:kl5Ks2[.N/ljfLQ4ռK.4 r"nՑyV(Q3b.Z ׁ\(3Xӧf!zBQg)RL67.2v7"1ji`uzq{8~x#-xf2j㷲?#\1?dyj ,7׃F<0܌l^#, -@43E 0] }UxMm&Rs؈'?Xۼ+Xm{p r7wxE^-̷jw=enbtMМC4ᖉn(jt:|͉<{z!jfy'ꆃ -uo{'(S~e+* -Yvys{(fkc4f/eg 3ڵ*h-%?/;7\(HOSgN WPzI("n6 tRUߵh0;ݾmcS;?.UPL) 1uu'TFUj!5^onu9ݮK9ϖxE-Sč „{ M-rk D,7==  uQB_ϝBD` Sx^ט}|މv; (pWK<\X<$,e]jZVo6&`ywd^yd7bz-MZT#JQʁUvO}P`GYgMz.P-㞙jY긾*4'ذ;0Fnͷ_84QGz6F7P&]=oƮh4̣}yBU+WfU#,{Coڛ~W-o ]g⡐KƖFGsun0L ޮt*7'u%|+!oagjDR!ȳS3*iFU +o[qATgHEM+N (Cr*](Nf51O OSY)F{?  y^$^{Ya6_FH_ n}K3 +Q,U,;C–JKo%yL$|p}#4}0LVX )&YGeGIch2D \8" ZҊ ,5@%)7W-{E>h n`ě&ҲzhtVXlCjݙ5 M69muvģ/¼%0C*KocOF^VCOez"D$1?;`6v6ęfޝXzS7ڵ\׍돬Qv”8Rt&\DH`H ?ͩ8]A:sG &QK}O6TRrKµbaLh/$U=IRZU ΢TI"vh%`R&wʑ BjGbGk]aIIJJuIB47ȼ*|sy$Up^dN UE&賅K{Gb4‘w5`- -: yB+Z`Pfol3O MGfI!6#dqzWGx?t]uxn92ף!!$3IJ1? ㈓|FHYCQO&Ap(c?fؐ h?&!%2JFE47a b曟iW^CS -~釹 s; T&9wn6Mo&)ȴ67gz\NԵBdFl`>ll :vr #u *$}xqGd#uA8dA-bH+î,:4BOGN!ORh7u? >}N04v0:.1t:#G/D$6gSoF )1_9nԡw0mA!+8ƦaUu.[h8+&v\NA|urK2J+K)zd4[2oTtCa/(@x~g/@mnHV C7&k4qM1 ۝.{6v`؟ᴀ{Ù6Qr T!3³ʵ$`O #R3*OPe1p͖B[- :|-wHbiR$=N@̓LH[.\^Qمۭ^p{,FVWM!%TgJ׻Yv|q|TUz!z `Ub8N@D!a bGQ&A=bHiP&]GX=hpnFԫ[QT ᗩz񕮥fj'~*,f>_39JEK^U@A^6߳'*&n'AaN{D[ bGei,ҔUog_ hH >N++Ƃ_㪫Jeܙ)r433dЍO*)iAOIA2QNqWf M_Iݑ@}Hd) \6HLOiIxi L7$G:`imVpƃsƋ-q*4=A Tl24~< +8lTߪ=$prz9'au4mF:sC6Ul3V}H${khVk(CMNܬys4(+jK  QBSs; ķroѠ7Ri7+jnԩ(hNo@8тRB74{$RP]HYyO`l@vlHFǘ g`,%JsR&, +{%Tf jDPRϥ%DvMT,o Ng@A< -qP?dfd.!囝+T'Tfp˥6|W\Ffro)ӆSB97*;fiBsr-p], RBRPȠUoP!8m" 0U,] oί7C C)rN3v5HuJS׻AE>xJuE) +=Y!CXJƹBd]@ &i VQQ 0KM3J<3 )[OD/ J?7W8e􈊆xQE̍+,=:u] :˩Ab-(|ebaGeё%GZ7aDpϒ{ ʘM.D5D27LoLF"<ԋ̤Y8s־b$?ߦ ](UFn$#W'42|e h4P"wŃOUT~a>*1ExxaCk39jUedETSj8/$"o=5AU+V|RJL-F _dPz^\--hn$|" L%'Ъz@R&W{/_Hغ wf<ޢ`„Ap̓w{۫ bio]694§/XBVEpId0:VsgG|S6$t(;U GwI tNTKoh,A1i|̵[aS/-ӄG)4bWD$͑B'n=kË9 /!܉[y/ Z.-W1&:b@/rqZ|\pGȚ鞀lܡp>| L\M-9K.-Ex7]W˱v070؛(dmjܕVFG1ej6Gulo( {TIb^ sMSF 59\st[+1{)َ'[el׀3tz:Bea!$ #d t|}*Bǀ%9"{{57ڸQtRY3tۻ; " v9WJXHGs[p~X2nBv=뵸IT?'DZ+Key,T(L۶c O [pP} U,D*b첥e# Q9bu"1TJxYĈQYD-hbq;1Yԋ\fr,RzsIOI/#"Z4t,u5b:Kg+1ʉsg64cbREAyRb@ϮM- kiGdy;(2-.3 )MVmɵybD GfKxS5|pbeƏ$¸q.4 |a*_/Khw_]WLNRRPQZ3-kI]>%?잔[T{~DY]JK%l--Ko-;ipAGNdz;CYدjÒ'nط'"kSYd#] S7wn /]?nЗH ^i,_ѐh[_ZEFNtG]0RԡUYFacnArO Q,,a\s5Ur7Q^2tY̜M=U:*( < %z:Q %N kcs=y{a3*'6A{!,E4yo6`މa {{cWo%̝XN5Kuv'EfYs(p:Qެm1M*._vebztbIط˕ ( i>#_?]aTyQDHd?p0G3\M#f4a8s(]d`Zn+v3E2q@]))t`"w "aߥz +N^D/DL6J)J۳OId8sƙ5hp:feRuc$Yg% B,7Iu.' m`_hcpS;icEHÃS.:vXGr>ˌMGF0k``]c5`򝾞x6 kܕ={DGXkf訴Vvę &,*vmi8]q!{]u :Y;Wþ3A AXGob&go{{{TJ0qTpZ5FM`ԈȈwcϭ(`ZƅmIAMCwW|3h݄wJm.{T@XlU S&)p6iա" |(4wG)?+cXacR/Zu 81C]G.q͏aEč_~ݶb Z-?Ł871%%߿) r@𕃡͐jֆ`EzWǯ6[diG>^PHTF>LUYU.ɢkd5!qr^xiV6i38X4x-R;7"`Ul#CV}Miҧ1 ;raOBORL2r4(MñAK!uJJ|1AleeQ"vh*yLCp(B9Fl\GfI+ Im1_gY;4(/dpJWf# k`U/u/)?YU ojCugX2HX56' _(4ݡ[bl wsZ/8ƴ;)GN䀟mlL5ʅYבؠ,AD'0qzQ(SYZ0Q_Zn_?代f±٢X^jhAYk D cKeCs>]*j}ǖ᯽X$<)ГułzP{?wk6 /øRO[7UY8J]9KK6O_њՂzqt., P±k y>+g؄ڸq ĤzV;DZ@ġgj&Nu-8`|zy^dQ&!?/A89諁cV/>Pтm:lÂehݏ|uRg{{Ro˙g_y$q]!zQmPR FmaMV+,"(9F\^xܐ w>y+efҟ#gj(XBuU-=R5<TsS*:5#JV5np6Bwkz)Y V&< Е SnSN-}扻E+ Z⮟mi^-l0$_. lʸLBKI,"8'C`r{!Ig9ӔQ,憶I,{M`rTh86h}7>EM]Y[ǚ8٨%!NN!cU9"#-۲s3n8@nz9e1У(Yo6u s-{0 ^rTa@9,֪s6fi"6&_a'tHtPt2!_y92 ӑ[B-FUhԴ‰1U s0ND"W A, ȁiSwi֙\*\q".G#Tf۵Nƙgq (M,̔rj/ U7[0`ot</3qF|yXѨd&ӡ0מ2޹T2FMǶz:-Pt 6`1簕/NYB@± s`aOe^M(|2{(3<<bܠyF}OPNFJktg[C7sKT&쮞x= W nn-oCe@+]!;¡7p&ahMIFT9єLeMx CI(m { \ˣ4SdX8NY&GxXÞcIh5vd`4Tz~Zp˱; 3l`^q+2˪Tܗ+,<p1P3OĿDN$"j`x~'1g3&ݝq r! ׭gRwb1k3B4!h>9I7eg>toƽ&WG-NJ\係^&Y"98]A.砂P*c`jd&3FIf *h5l^ .>y&Ѥj~ 32CpNFCM@f3] H s5*Sa"TAZyOy}( eе8:5reh`o-j%~9yǗX`{*K Kw,*Kk@e<溨h|Y@XjJ?-}G$T%FύDŽ Y!QN??׀'ځ^n09w'*2r-'f&(ݓ#S۵^2֧,]ΕAiGq8wDqo$ӹ!GQqhdFm[9yO Tbiגq#6\9)l<v,sЃSlv*jVIRJa^b ZEz0 _AIKMnIݺQ/HrU֏Dz(n4{,&[M\WF6w5 u +G5n kxrDQ*ڦe\)irB$ LXz'Bs%!5Kt[`폰 kIxQwl\j`uW(>ODVb_K̵{tWܠ%iԱ껳i\3OJ,}no&:`eF(ȟ PwQn3vIJz BG:vf'#s QJ3O߱Lj eF!xRxU+|afTЧrXc pyk"VݠkCAQ*S@)LUȃz; v՛vy͇xLMGr 8h'WmcQr]Yv?ֲ(zOkz;Fv|yaY;~4>'ГȖ~2!"$ ((2g ](nNSc.fJ 4V:I7w4=}DzmϷSqX՛#@#{BOhm䁊a &Pmh@CGv-:NuZTgix”<4OX]M U.80t!Vn&]5NL/xz*jqx-~m"$Ez,/_I'nDJ8ؓxBͩىNtXu-=?sr8si.};zAZ4uQα3'*[z<⺯y%Nj#JqqԵBTIWu2 >}r@n^;A|w%* =G4j|0ŝCQaZ%k]zļ79Myt_2XfI-=6سYu/ce3r1v^XÅ{JT<499tp]"Y 2v?_*t`zm(e^7OK<\#OEt@{eD8% !A3싍X]$s=&&#x؆Zr/%,ԋvcs#ĹJ2x%@kRQHA*CDML-;q<ňN!n%񷮍hVOuM06TLHo1<`zu L&0cŪTyNy_!W(qv;o䶀:#ui2mv;ei`O|ltCc\i"#$B\ݵgXh$J⮉3ro! cNBJk¿Kl2Śiobdu|ӒjT]}_ lZ.*4A !<ңp^?ќMB:b:Et(E~-<<2`>G÷իibΝVM%Ǡ1Ǜ(p:׼I/n#4ogImSNMJIff50ed}lakDC$ @~T6XtgJ^-* ődwF8ßqH(F.~wY#^[lG:Bh9F SVMc>6zQxK -n:95&w"0qqqL_*Ld}yj0＊ Qî]iRg2\nƭ͉p]wM5Q䆴c"Sp緺ZHY~LU˪ǔ$\xf]qbHtt ;&gyH14 ulW?i#2Ƥ_OBE"TlL&KT:\Ѭrqצ$?5[wZ%w7YZ$˹\ӮI H&]=a!q}UK*'wu0AOd.%F3)U=<.4AJNJ_;VI7pvJ3rYEky35AD 6 <{w6$200]˲0z_f\@Z+K7Q;Ù5B~xeidn|l6F2Rщ-d9j'fg3Y,'[~^nе'-^NnǁNbyJgzPZm7FHK@k@$Dʥ]k4yU"hhd5AXV)sn x9FQyXJJ\|L*ZVz~XMӊR:$%sy v1[1+D4wt(KʏЧ`pG(~@~w??6h઱frrk*-op~R %oG܃6g'>2B,s&hZž_)twXi8]fmYo[Sݣ`4JWJfY9ݤ~| f%ݭi˅ꆻ͡Լ|-(k^mre0]*OgGcS~9@zdZԛ3}Z.'\ké2}ul"ׇiFk+]KbNF4OqB,{'K+f X*daF[HY*<`s*` B]^؋ u}R>6cO< 0wzqSc s|bΖ3IôcXø'zH{ajESG5 QחL,7`L;c_a6aHp0{ .c`uZ{@OI'³Rǡ `-Civkyt7L] c`hrr=R{u4Jb_ڴמm؊kFoz״ ]@K*fux$@S+0`~1~Βֽ!2QYV* [hO"Z1Vy`WCMޕyUrpŁuƴ2/y "Zb%;ԝLQH_/K:A樌^fc]:j"L>O|jQZ.m+7Ы `$eUz:įO&E3:Q*MhT`۶'d<憙lQ]k9qc1t*Q(Ў]/\bꉦ3VsZ|m1Hm8_8.Y>XMy .կY٦nUDHXϡNs &>,-K-IvE噧qJ:嵸~qdWԒ`9bb'YLdUƊ\D7ȹ*HgƎml|񳦊vڎx S ܁M PڽJ<Ͼ )4]"G_¾Ld&jvNiq{̝Dka6BD,<%dCV_E FJ8 hH<=,1 Ex^g"эj=68R#4 涥-~INGpdm:,h?ė#C@n$)8X`l[-ADBэBG(@M׊pzgV5֥U"ͳvֽu)Jnj8*M<$8 3 -7<.Дu3JrӐ_X{z& ťN0,is uQXvDP*0ddq #?ڧĞPRCAeN v TV_dwĎ TG<5`%=5=n(zȯx];h xrʺf8UX׳pV ׎ל:@p`tRS?a¶籗mxeUFR/wpG1 ]m G4dԵKmn{2KN$̵ZdZjpP m"ljnG)WYƹDmtℹ4F+0_WF}~pc4WGÙFEjԡi) N~(wґ\L[$02 ЍW- 28&9.ڒZe[$+v*|ܪc-p,?td,f>gQ6&.j82I~Pr~m|OJ+N5D%c&n{T &LB@9^U~+2?T(/!C{EBa>WA#m(j2 ~7ML<&/- ֦슠/=knFWxRMN@t.sfӴӏ,}d$(` 2sgEI}1 c.1qDF}6Hd\qO#(HQ:,g2H<P^7v፪]LIAԤʣ`[U2R=b[˜|}(u}Oi7qRF#={khz=`!*RR,N٢*)t+lr,cB;AodFyj]}}3Mh> ֠tz E6 OV'T{BVUĐ% pIj &:0h׆QIiO 5N3eZRbAC}uWS " u:& WiwqP# ŝRiL˄2OJLFVv%Ϊ'&eE*[6_gYl >aIaP8V 8z-^̂ꅒRܐNaR:m\du%G魆$fr7 &C4E YM4]::Σ6W,ghZFh"C ^Ze9 v_ݔZU;ł?@i7En^x?alJ>JF>ƌLZ.Qt<7uSZt1r=XvS6=m`dv l|ŇGȇ/_'!2nMmRps:w"x:(G;GD7 -8iGjpBciqrC/S # z+Y]=9aV<ދ_n8u @: S ngVw y#-vegAlTxJlc)O|\D #g;CuSj>N`fvG0s t² Xen sXB9Q;zYdl;MהSf9RpL'\M=qJCje]s;bXˈg-n=y.J+:;j gi-˅#@%Y=:MbP_O ͢+:-(]ӂZ5{:̅̆ *l*RU!Ȕm /s͗Yn*g[6r-2%Zx!-x/۲#2m ʈ2q2~'Cse)I% 5Se{1Fé:Ҝu'L`ue9gl=ȆSFIC皑* mX)TW`hSl>/'`Ji7k%}ݑd{^f.H9*. q?YP >64,\?뙾uFZ)JRꎣ46EXGs-2_VIE ʲ8aqHd4s?\;!V/J{J4OÙެ<;5N3f$ˁ33h aj \-@Jzǁ% zkI˵) ͌\lHE36,팘"N!,WlxbݍxZːBv 5E8D6 c5:ݾtWE]iipm1SwTru™Ne ' A>\&{J[ۥJ} .Zۯ#C*<hUSs[(2}(SG?FIIX"i&Л jqwuVra[dX0O sUp$gv )s6QP"4=l?"zkkt):)(8.컛uu^ s@3cq~ <_V وf(@"AwH/h#.!0*UNP7a8=G+,Y-,:bnFzPXE 'fS 6+d%$8j+lj%'xOMU-mijHNV(eϋ?ps16Aޜ8"kˎi~iO$^;-tuUXjE8P`c4K#QA)Δ$UWf!Sf,Y-P%tda#M@8 soWGM``.=b)s s0T&^ \#+W@?1=gfxSukOD`!CB=%1ͻVq -=qQ>\ U& S9`\t@Vr~*4.tFXF~ţDΘhX_Vv?ƬXս+.1  =rǬm\ fh4U; BzلI"M\U;ܣ<V" .ηL3JNv͖ G. ܔd_Ytb}F+;2kz%_di0pZ~0Rx #$B6p"#1Ǫ$VEXq 0q*.&rN )?~~b4"hOWMG̹P:|B*rHFHuqݛr&jF" -%{> U$o nԍ%JY Gr2Շ͗dR5 }lm}&iL7X4K`rC>'R ,b6_j,84]Sf3Ls'D!4ylGxgf0{x5 "=UVoI1($*EgïQu&%<L[9:TI&ѼJќ-G+xA >-=TߥEq 𪇘"*!n6u\ NFqHBL0(jjM)VS tuL YzSuTF|! x4kp;fA@ }{Z6Z.u0LlO 4}ب'īN矋~t^Dϟwy{?:xDe?p+dmj2@-ٸW" Q:$ԟL؆t eNF)8)@Fn ]ɂwi/<x 4Nt3Ss"2`{Lzh#k:5 _k_qv1%w1EtIgdOfފc $]^^xnz g{5`L9 JgA`&|bz~S}e~6`^^B4}pCt7 1/DRl iVgߕ3@\ |#oP+"o)\|9{$^@jY/ج*э8N[wQyd;0)`S${`WtOq➒7oĨ52JYۦ޵XqT6. UAΤ638f1~YFnSQ;yL*Vqtޙ )v`ðT_~_yQaC4Ѕ7<)+: &eF"z.ēߺZj7C aP/KgLQ<D/@kP!1މo꫙@-1*0?׍Qi `}ZE"!H)%j Ze:86{sҋA-RRԟ> dkǺ5# cQ/XSJ{lZlÒgH(t;V}Vo0%>ǵHU L VRȏ"멍)j96\U;au6HxFdHVD o7 ,;s(w|D ]wʬU:q܅|=?8]d#Ow33.ce[5bh%a`ҤM$CCkAE2S̓b?ebYѢ%haOTg)[5 ɣnjV&NzN2'e|d-QY 7Z?}ᰄu4]#u)pS7 '"@I,9}t /:YX4^P j.`ʳ®kfr%BM ,*F=,&;0K4ثB yW;ّiǽ~Ux,8` f"SEt֬:im˓C]Z&?U ]ȞVBJ"cՓoV*$xD/G tK$6ȍ:fa8pB{o%:2ښ/,B*<=^O6l˧C+bivɉusZ%;Ҫ9\ҚxG~뉼7EW.r4MgvjCRe^_i3ZE'Gꀿ9LF uH:

М) =ڳ< =zTKb/E~dMy:~s\hyp6U\Н(EܰQ<#,fa2/T*)ȎXfnQ N})꼇*W74H~p0>3l_=Pd^-~v"1GLf”f;},BAG{2 ?/Q .zIAT }* C%:KNYhF.zFVګ3{~^ıF/kpfׅcԥ{FSH%0ns f^̖SdkN;ʻ%TrZ`2 R@VɼnbBC75_e`244ϦӺZ<LպD PyFQOV}i#7K 3_,el3AFn$>E $W#ݗH"Rx,ӒSx.+'ss;lqxxN.' ij m/4dT|Xnʳ k5mO)Gy[m<;cTBPt={EidҫMҢ2;")ivh@#=<v9'5͵˕҉LL(߃ a$t%s/ŚAO_*ͣ3Feu`E,K!|ӏ/bs(e_4 Ol%OlH{DUzXgƦJm}NtA odŦ!~5o[JxZowWy@΄.}?k͇m֟ &,eƁڃ4@yl@[ƲO>Rv uŝ.Mnn9Ԉ$> [Q+†O6xM,6uN4ABG(bSgJƤN#,ϓ>!a9d,'H0=}ZUqI߹EGBb+t'k@\%ہ)[ 4yG r}߀GLs7 y#EomitdQDSw /zyߕ]Gmke۩},S:䃄Jx,9Gj?[[Ti%8-Ub4$ B%$8BH7Vot:&>#|gM2f1 ہ*Do_;[1N}}=kvv <?UsُYcпh_bªY# =Hg JQcÝ0Fo> >*H~mTHDo4^~{??U豋[A>Nפk/Q[dFqqA T'F /S磖$.b!dSK}:hw!uw*XUst\֜>;l8Ѷ:bPW+Akl<0.`9"a:efӝř7$oh< ,u *"6$ֳ+3QGG7_}|H1tҍtJ(֨=O{`CN-Q̆wCO5 [Tpõ7^VeӐ!\5˻1qhLAІ>nK $Jn}F٧t0etY]~AU 1Sv9PK9 'ƙ'sYorZ-j`lQ~0T[8sͦ,QBvQUChRњ4XAl<}i ƪ@3r(b0f9xmz[lT6#gHfMf~:Z(pJs|Oم^bݞ }/᧟}#᧟#H}ϼ bK }=A\" @-mʀqwۺNqZ.tڸ (WX0I3Qg.~u~6Ab FCP1~yV؈Bby,- H;S/Z3m?J\יH_#߼w 6xt|yzX|3ᘝi[+XC0p~jGYꈒ^zϽ,_谻h?[R_v(YciSoծ5ʝIr{  Tx-̀oP-F^dK^ed0c0f|!|(/{r={2g_6IW d%E?pGm:r6" bxyzHf&LVnز[OHehxM"MUdP> 5TJ˭/M5Ǽ8 Iuk봴}gg{^=w:2f8tS[~mfüI-xN2A38ׁi6(J{I֣Mc- !T:ȭNH=Ic@D 1^!pp^[f^60БQuQDufS2P ? +[Zڹ^zfJGqA(tKߙYƫ+_:ZZ )t\t 0>)g_ϑ)/?[& Xd"5YWC:Q؜NZnzG,"ʥѫKSf2%zE:륷!P(M˷0 MyA1!EzB0=2%ozW2.kz(% 9pt&Ų1,"M͓os"˯T=sӖFÕ7y,xZ ~I\XeJz;H-Gm3MSMj4uXrX~]< Ұ*F>$(!L Xesa!gQ [¸1l'a.[ك[M.xAd8w& y,HY˨ud_f$NЫc a9e_$+P.LW c%愘 u}c㸜G 8#}h1FMpԸXU-sWFV:.WVHGo"cA)NU<}R)6PC*/Q9}w<:wk{*O:?t"r6|iNWI$ꁡ ` t"2n4=L<$q#pyMϖSnvTRdtu봩gw/}k[]'hQsO"}h pn y䘶VX_(жlGŖٖz kX `^'#Wsmqnz(06~6IOi*A:aE=I\6jD,;9pr]ؙL' wEjI"jQ-ӟi 5>h4M1E3pc1diBS\lj_/ی8  pqt~A)f@h ǁ\Fz\BVc ,)ɩS>\U[@ -X˫ݥڜՁyghDG8 >Yċ'zEI ʹdBbH?nVJj_t [`=7S\DF[S:LQ ےCvK gѨlEefyaKI B,zte|Hd'M-ugզd\6sv0֏jDt>y:}SYul}΅-tYr"40SW塽PUw n׮k}|ނpK\ | 6r .je4($[sګ_P)m5lӉYYR0ŠB[8"I<CQJCJ耵ha%ͺKhgtlF=ØgTa &\)ܐӍ'X?l].κ\ػMpL$;DcpN]1I9TGG~k>΢uygS1ܝgGļ*,?i7; b,S낊T^FS,yg8e}.eZWv.7Dڑv)5ܽߴ&AAOBaEce0tIX$SЖt]ʧX :hÉ# ƫͩt4z1^uZ_5W&a,lۘD-+k/Fkgy*izmqS |$ao3g+mm"y`S}8b tE֨1ɲ8;u| x^ZfK*# &HUGwE?_$x5'zbc1C{nBݭ H? lP,J ,c_ƻPu[TM,xcK?  C S,eܪ]nuIJ6޴AϧxaɸmdE%}x)& 'EPXZ`ei2Kq1'No )%rQ+YzӼ5z_|}9e"I#:5ey`1>[B~֘&CSB#]MfZO韟gY`ƻ4[g}b%~XV!Kkjb<ՙVJeB+yp{d)z]w]xh&W{w:q&=L'CU?%j-LOŹhc!i6׍x ׈PglJ;~$C^A6ȼ4ÚŅQNNU% ô#{^\+6z 6@;BY)!vd˦zdm/̱cSvdGXJ4}M֥ =He H ad% Ơz7 z-"ٜ߭t}Y8^O9ANb6Þ6P׾Z #+]|:}uA(܇Եor,nG@掭.AR9U!s[AwI#$5C-A:}}l3bP7@Ab9sWL6\ZT-el/v˃u:aߝ&dMnN}Y1߬iNq $Cw 7( A]а߱ZAv4d^% ⟳|KVј&iqf@0AL:G(莏&s0UeПogLsj+byvuo%~PWzmϝrʐT%YSpJ”I/mM}ɦ͡ΌtuZ8 f06g]9*D݇]d1_43>deo 2f '$jCq^e;Jcc "Jǎ5\Soes4,ګ۸FD}p[=}NO0(IRK洚|@m,]u}=V+ f*W *}5w ,ý#'Ǵ. d Q6E:KzJs%Մƥvg_%ȼJ&G8.Fq:ɧ# tf $d& 7n<'u*+J/^X]"605| 4P&8,p,gL&\i~0ow7>?}&wd:<.&"6/fyah{'Eli6tv,`g(CD$Imi ²ۭЙI菜0|p챈Օ_σE~aj)s͜&YVVpY:;:ń &!67hp~7m]%x"%J8~Q j;ͩfȬF/U(gwfuX0?ңO۸D_Fj=(Fx֬$#}-|".ԠuYT4V683~}ȉ^@Wbה99Ujꔻ{^8/c?&:6Y,['aDZK2=1Fk\S: ,ISA UNDo ރXx%I:!.0V'U|Mn&5jos.*Bjiɋ!I -nrɊd E$ƘY H?58/$a(*i`Ӧpvu r>Xe<^tm?|o:PMIt`ZgQzSiM.)U[z#I$'@5(R?8ɓݽ N(h|8l$Pl9(#mݔ>-(+mZ ˀR#DƘgASM=br4MlxEqzw 6pu[u~VV-(n"^6׍_m[<4x+U νk?DMxE1Tze}mw0wP>YAb KGisZ^vU"ݾhy.!QaKJ`8# '&bq\|:qGc0HO]: 7zZ0of2X_{]52%2/'V1Fxzɓ-)ZЍu3"c#3s'-泴,;= Vpz6-Jo ]'^gho<*Z Aq6*vOO2i6>A*LMZsΐVQhL:=]#[dy=Gʧ٦#BWW[[ yAtV1f$Ѯ ݢ8D*kl rߺ/mzMa 7msڝi5.\ԝFHrGRp_}@}T&J?/w+z8̼=3W|U̜ypl"W5²"<dmzJx0 -|-E) pؾIbRKfF0\$Jg+ Gw`“4X ;/ ƧݞY> ƚ(GJd`] 9:fq߰ⲱ}W|:-j R5Bk4*smsU(BN"pMm@ȝEҪ&̵f0VgKuE<ݬ]qe'M7|\ҹ9OΡ/gq=]^E\,9Rr_շo, ۖӑwj]n.[zO=ۢuZPѰHUVՂPu-e:9oAQ1ce2E+?AW \}7]ħ/c5&nHgnPcbDn,uiv787MЛ{WaAWzh|1묛_5ۼ,7C;]Y~ਫ਼uz-hl㤛}= I4 -ڍn֙Im{b|xzՋyy ӻW!x+m?~HWj䨧Y?׺PMvl{_z39"sW7if mh"iߣݰu~ލga4it fio0m| a_ot˶Z؄U7gz/O#L7*<<U,Ӳ_i{;18n>N[qp{^8# <'LC;i @5^w5Cq3XӅQ,`'Oa޳MURUE ᦖzZT)zz3<@ʀ+uQkU1D'8_g:OWmFOUbpXtwN6 xND "i-ﻳjF>] _+v/Cd얃)~/o[F6NԃD_$sq 4T/{ćspz,HAk`[)Xgs|=kV=9b4-OuМ'Y *?'5'?}\M~^~>^^էWP`ӣoGm^4<^OѧOWw^}j|>|?|8=l4@鳛_߿:Fف"d_V#0 /F#ԋ!R`uMF׽tc.9^Lp+X&3n `d{^ݾ4y޼hܾnqCOX_TWfϧ>_gW/ێk¹ۿ{qfΐ8Kܻ]ptLvDd=%hL7 Z9إx ]xcRQ<~ U7j8"KUy Qhwz9u,O[f0eyNz>@1Q/q鍝Ah#/O[xo >́BGs h>aw7RUp|3r ):h^޾rWcuj0d7K^`г=q7w—Ij5vzz?DDyp;T*^|Po>×.n0Ӌdp}mw>\ ^n@&&$pdC9Jvv:JkJN^oZSi1lޟ緯F})-h5gˣ*< [nޟۣgCut,ޢl7@gHTq}q1r_l/Z5_*Ŵl[w[%$قilsQgaYz}U|ܟtEa݄-6SRGԿ>[2Vy3w8T;Ço㛳侉bwspc\|!wԆSu]l7"=?O[`.d>6>}ξ_[׃eOB t<\܁!>?L hݱ3CrL[#Oun8y@oO%@!mM%@;C˻![)-؍5 5h?mmo/a jӰ'H?S?bƛOdvZ "`{|ZSx߾ܢ! |B]S|{5$hy^ma+OGx ]Cp\cy)3(uAD]LZWU )m"= G3?̈is(]890-Ru'E)wj [^)g+DUN!D";Z}uVBVQ%O#XSHGd ,J+c&U<`J)d rBIA0:ZZE<%[1׾1)6~l7Ҥun1rZ^.-v e.3F1,HhzpTο}Ro!B!#@,wp)+[/wMGs]mփޠ"{ϿAvh]zsB6ltAlN_[GLJޛz1G${>oݲ&jESyM,GŁ7ݿQ{p`r¥zAUї7^LQ} M/Öu`E> d~hb`⟥M ѿ ߫աG(Wr>S͏N|Kwo~OW~G yܛ^kIz\Wgei" 0Φy8Pxe!ӿ >r/O%S"ʑkI}0$8U{ί~#y_7H464_o/lUa.Bxhr ,#.`s2"@ ;dpo"tDB̍e[;| og?rF?~p:/"POFq'do_!,Ӌo0f2Hh8dmƓ.b/?_.>&J/#׫!ݥ~+$ #;=dVDQ:wj!XsC|zU^{+}A;L4<&X rnGx ԽQ\m DB(Gp)2B'D` +`Eh2S5@ $ʗBڼ]f`ТcK;t{;@ůؙ<2HZ,1(X~߾ղataP=p_dJ "(waAW5UDJmDKH3 !S(tNnDeKԺts|.Tp޼kK] fzR26AZoTۥ+(P]g!Vh8,T&2H41-;䓫@uJ"(4Y"׋LEVI<+^H˳}}M}:OrQk.e_m1yȋQ0+Zֳ~#PQb_>Wfw;8Z \>L׌cߑvCOA0.MkNwvwp^din`cn3~{@A<<~3/>h";ez;q0dewKVbyЉt1Y4n5.Dۂw1yp^Xm&$~1%#Ge}{;1 >~lL~U bPvTv8q1nƗ1\|K?]]4/goo^qpl?~ǩ{{wݾ}5?xws_}qm0lWۋ yS~sKkS~1/A<9]n_-^Gj_fo/OͷzyvpJMj?&TS=oo_OE Q7bc^<]H?$?o_p\wvm\K5c.I־?2MFw6< }S η׬ݔ.G`?n5>* .M!pؙ^\tnmվm>/6Ҍ>AqTß~9Ylmkᓷo϶7ߖcWϷۇwmlH٧oڬםۑ_zpexN^Ƣqӻw4<~+ F|n>pZ=}y,q}:X^_oη{ip51@tWF|?_2:mޚ{\w||NF|x{7:@䫱_;}?|i>{u|u4ikAGpuy>FtPS_ﷇ?a}g>׼4foFPSeOS?u|x9yuzc}o_mL_<4 ; ozp|ܞl@X_HwyH!=<{QI?ڵ''3~}xvspl;ip׌tW6}k{K|{C\V? ?޾LhponϽ7}!xxp4m^nxr?u^_<_~y}go}l]~noO'߾w1^|~ټ1_߽tϫw7_/QHg?O#BWaL>}v.no?4߿ťw]|pxL_'G|t~239_wY7NRhEyp28h=k|wο؋{ʗ_}u0 OwשQWft^uCӧoo3ř?ߏmt9{Nwξ]: N/7adv+I&<:o\%>ޝݷƇo-A̩i:_| $|}i{_^z}]:TpԇC'so{؎ߙO=ܽ w߃_k\_pniK8͋ӷG/ywq޼zVut޿͎ճwҷ />4GOQ:7^}[BK^4ۻZ|~;R_;/'Io$>ۜ}|z ՗އ%uQ27kO +/>|3^iTJdzAc[w0H>W׃ Qw~0epuvxx~|4ۛw};pZ ˯óai%R)x}R%`E^5lh7?Ķ d/ :`A:W/'=LLg7NdL8)VGn]",얚wfhUvas]_}.y%'}UN5> e^Us0b yPbJ-ׯo/ ڞ}{,ooorT1%y`\hJ`4jx'e5ɯ^$;x&t Xڶp/q8bd3]4yK壜3S]4Dd9]9̜V`8L "wR< .7gJMl}rl?޶\KXowAN.pK&< *o9y;M/,\`ULZ*UB"ޔg}YH\el2G Ɉ53 [7+Px)ࣰ>Ws׋,3Xl&\:ſn{pq&'܈_Q]}b{ >EzZi+??TM*eNSlswAޱ+طw& Lr8P\3ߊȧt2KwQ|y7 {z?~ޛw%g::h@gw)t^=&[~_Ƥ0N~Gһڥ͆H*œ I)tWf{:$X%2+,{A7p{`+/jVm0I&AP8_u?QWIK"KX_zphp{!iSi/66W747}/qCչss$P뵤UsFwUt|RoNN$vojޏDBQGAX1:MMJV1gԠzV, =W?M;j83cT}g5{{%Ff zۉeo٪ zaw(<ɢיOMEm9eò&ivo1)̻ZG2_[5_QKOf0N"Mh(VW^搪 I BwPg'Un4$iII{ 4h5qyN& S/f+Xi#|;eޘ1T{Z gѴ;ȏ^XshG܍aw &C괾{EF]?J#;ƺS68G;n.]QHmdkgY:|o"_^4f*jz4 peo~KoR߿;.|WZ hIҫׯ5 ޝg=vӀQ͝W4qfic {rka*tR-Iu,l-K9evMY{/PuM@yQhT[3y1V}c`iC/ci0H;Ad8zV6 mV@\g#+|R,D,J=+P{o9Dy0)`h J>N ͣ`IvXK&'(e4U۶L4,\?뙾uFZ-,cXM%Ղͼ ˠN{ןf0wC;3S?\ e "ˤ4D>_.@;c8M](H<݄e:eۃ!Ī/8nҚK~sXF(Z~_,kckM«OWwATSƉ $^ڦ$'1n*N6["&ݬOBG.9-:%r횛Buu1ݕ:Жrϭ7 kXLfV6މڮ ^w͞;bX`bހ4 F?eQOrjM95֒3z6]rUXYE2cyK+{̍h؞3>@ף~>,MIV2X9K&v*!{ zͳd[߬gFb#+ e mljL`]@e$؍ߧ_;?|BIqʪ`5w |ɔXW1Ĭz5˫ !v-,dkXc%@q6]̽\o8 7@ '`k/;*u R%/[m$n&ĿC~ݤFWu84PFuT Sʄw?өO2̼6$?='?S^żIW` COP*/IA(G\!Zx(hj!;`M gekaMtd [I Uȟ`q~Ӌ?iTu DE\$r`rkѺTSж\mhDY`)+!¾;/ٺۛm#7lM{U+pp0v68mI2M]#P0ó"`^a&]=pRhj¿KEG;fr ѭ6'h?^S5Wvo`,azBiZzab>!Zw,";ail>u 1T(V "QCPyw!,xاγUiP`7^#nU`vaydK1W!g3""Gs3%|D!&° {dt"R$2?Hg"UhKWQȒ  +kUD)"ĬT P rUWIh=Au o0f"w ȍ0XSZE+*8رrVc9b6UX0X.܍U1t+'Q=0yBCm)R¹Y !Qiy˅sϝ A)sJB0n;0RQTN 0nFeYoleSآ(2oꝺ*jUeO(vVa ,"5ta8^_ \pRY4&z/ YF+d \ l~UA`o DZu]-Hߵrjv& 񴓢ЁQH,bo CD{"*C⧜NaW)N;[+jUK]32W);JMMAk,%W( IS~\!}h6Wn.axpXyܥ*2stt0X`f ayq3Kw*:cGN德JtyQp A8lt ke*X x;3^Nݣ؍c+RPMxm j♱4%-\F-nNԱrjO.*&ln2!PnߝFÁtfgޠ~='zDAF;4ǹTNMM"HEN '.Z'i `x&*=n6e8ȁMR ,-8l=u?pׅn؂4[+c9D&Ghj:6qF])/a쫇WXT K]8]̜`k 0Ǜ3ò63vp& QVeZ0 p"ڵM,R.tu.6y섮д R] 7ҹogx~vj4r5懗AܙRviu\aQ%Nk( Lƻ5_[ơ=G'T1yB.?'AuI3gcm|j˩NL%#U4*5)oSZNuJ+\/p GOVc, }z oI\dMGj:K@-.bhNt#m:kl5Ks2[.N/ljfLQ4ռK.4 r"nՑyV(Q3b.Z ׁ\(3Xӧf!zBQg)RL67.2v7"1ji`uzq{8~x#-xf2j㷲?#\1?dyj ,7׃F<0܌l^#, -@43E 0] }UxMm&Rs؈'?Xۼ+Xm{p r7wxE^-̷jw=enbtMМC4ᖉn(jt:|͉<{z!jfy'ꆃ -uo{'(S~e+* -Yvys{(fkc4f/eg 3ڵ*h-%?/;7\(HOSgN WPzI("n6 tRUߵh0;ݾmcS;?.UPL) 1uu'TFUj!5^onu9ݮK9ϖxE-Sč „{ M-rk D,7==  uQB_ϝBD` Sx^ט}|މv; (pWK<\X<$,e]jZVo6&`ywd^yd7bz-MZT#JQʁUvO}P`GYgMz.P-㞙jY긾*4'ذ;0Fnͷ_84QGz6F7P&]=oƮh4̣}yBU+WfU#,{Coڛ~W-o ]g⡐KƖFGsun0L ޮt*7'u%|+!oagjDR!ȳS3*iFU +o[qATgHEM+N (Cr*](Nf51O OSY)F{?  y^$^{Ya6_FH_ n}K3 +Q,U,;C–JKo%yL$|p}#4}0LVX )&YGeGIch2D \8" ZҊ ,5@%)7W-{E>h n`ě&ҲzhtVXlCjݙ5 M69muvģ/¼%0C*KocOF^VCOez"D$1?;`6v6ęfޝXzS7ڵ\׍돬Qv”8Rt&\DH`H ?ͩ8]A:sG &QK}O6TRrKµbaLh/$U=IRZU ΢TI"vh%`R&wʑ BjGbGk]aIIJJuIB47ȼ*|sy$Up^dN UE&賅K{Gb4‘w5`- -: yB+Z`Pfol3O MGfI!6#dqzWGx?t]uxn92ף!!$3IJ1? ㈓|FHYCQO&Ap(c?fؐ h?&!%2JFE47a b曟iW^CS -~釹 s; T&9wn6Mo&)ȴ67gz\NԵBdFl`>ll :vr #u *$}xqGd#uA8dA-bH+î,:4BOGN!ORh7u? >}N04v0:.1t:#G/D$6gSoF )1_9nԡw0mA!+8ƦaUu.[h8+&v\NA|urK2J+K)zd4[2oTtCa/(@x~g/@mnHV C7&k4qM1 ۝.{6v`؟ᴀ{Ù6Qr T!3³ʵ$`O #R3*OPe1p͖B[- :|-wHbiR$=N@̓LH[.\^Qمۭ^p{,FVWM!%TgJ׻Yv|q|TUz!z `Ub8N@D!a bGQ&A=bHiP&]GX=hpnFԫ[QT ᗩz񕮥fj'~*,f>_39JEK^U@A^6߳'*&n'AaN{D[ bGei,ҔUog_ hH >N++Ƃ_㪫Jeܙ)r433dЍO*)iAOIA2QNqWf M_Iݑ@}Hd) \6HLOiIxi L7$G:`imVpƃsƋ-q*4=A Tl24~< +8lTߪ=$prz9'au4mF:sC6Ul3V}H${khVk(CMNܬys4(+jK  QBSs; ķroѠ7Ri7+jnԩ(hNo@8тRB74{$RP]HYyO`l@vlHFǘ g`,%JsR&, +{%Tf jDPRϥ%DvMT,o Ng@A< -qP?dfd.!囝+T'Tfp˥6|W\Ffro)ӆSB97*;fiBsr-p], RBRPȠUoP!8m" 0U,] oί7C C)rN3v5HuJS׻AE>xJuE) +=Y!CXJƹBd]@ &i VQQ 0KM3J<3 )[OD/ J?7W8e􈊆xQE̍+,=:u] :˩Ab-(|ebaGeё%GZ7aDpϒ{ ʘM.D5D27LoLF"<ԋ̤Y8s־b$?ߦ ](UFn$#W'42|e h4P"wŃOUT~a>*1ExxaCk39jUedETSj8/$"o=5AU+V|RJL-F _dPz^\--hn$|" L%'Ъz@R&W{/_Hغ wf<ޢ`„Ap̓w{۫ bio]694§/XBVEpId0:VsgG|S6$t(;U GwI tNTKoh,A1i|̵[aS/-ӄG)4bWD$͑B'n=kË9 /!܉[y/ Z.-W1&:b@/rqZ|\pGȚ鞀lܡp>| L\M-9K.-Ex7]W˱v070؛(dmjܕVFG1ej6Gulo( {TIb^ sMSF 59\st[+1{)َ'[el׀3tz:Bea!$ #d t|}*Bǀ%9"{{57ڸQtRY3tۻ; " v9WJXHGs[p~X2nBv=뵸IT?'DZ+Key,T(L۶c O [pP} U,D*b첥e# Q9bu"1TJxYĈQYD-hbq;1Yԋ\fr,RzsIOI/#"Z4t,u5b:Kg+1ʉsg64cbREAyRb@ϮM- kiGdy;(2-.3 )MVmɵybD GfKxS5|pbeƏ$¸q.4 |a*_/Khw_]WLNRRPQZ3-kI]>%?잔[T{~DY]JK%l--Ko-;ipAGNdz;CYدjÒ'nط'"kSYd#] S7wn /]?nЗH ^i,_ѐh[_ZEFNtG]0RԡUYFacnArO Q,,a\s5Ur7Q^2tY̜M=U:*( < %z:Q %N kcs=y{a3*'6A{!,E4yo6`މa {{cWo%̝XN5Kuv'EfYs(p:Qެm1M*._vebztbIط˕ ( i>#_?]aTyQDHd?p0G3\M#f4a8s(]d`Zn+v3E2q@]))t`"w "aߥz +N^D/DL6J)J۳OId8sƙ5hp:feRuc$Yg% B,7Iu.' m`_hcpS;icEHÃS.:vXGr>ˌMGF0k``]c5`򝾞x6 kܕ={DGXkf訴Vvę &,*vmi8]q!{]u :Y;Wþ3A AXGob&go{{{TJ0qTpZ5FM`ԈȈwcϭ(`ZƅmIAMCwW|3h݄wJm.{T@XlU S&)p6iա" |(4wG)?+cXacR/Zu 81C]G.q͏aEč_~ݶb Z-?Ł871%%߿) r@𕃡͐jֆ`EzWǯ6[diG>^PHTF>LUYU.ɢkd5!qr^xiV6i38X4x-R;7"`Ul#CV}Miҧ1 ;raOBORL2r4(MñAK!uJJ|1AleeQ"vh*yLCp(B9Fl\GfI+ Im1_gY;4(/dpJWf# k`U/u/)?YU ojCugX2HX56' _(4ݡ[bl wsZ/8ƴ;)GN䀟mlL5ʅYבؠ,AD'0qzQ(SYZ0Q_Zn_?代f±٢X^jhAYk D cKeCs>]*j}ǖ᯽X$<)ГułzP{?wk6 /øRO[7UY8J]9KK6O_њՂzqt., P±k y>+g؄ڸq ĤzV;DZ@ġgj&Nu-8`|zy^dQ&!?/A89諁cV/>Pтm:lÂehݏ|uRg{{Ro˙g_y$q]!zQmPR FmaMV+,"(9F\^xܐ w>y+efҟ#gj(XBuU-=R5<TsS*:5#JV5np6Bwkz)Y V&< Е SnSN-}扻E+ Z⮟mi^-l0$_. lʸLBKI,"8'C`r{!Ig9ӔQ,憶I,{M`rTh86h}7>EM]Y[ǚ8٨%!NN!cU9"#-۲s3n8@nz9e1У(Yo6u s-{0 ^rTa@9,֪s6fi"6&_a'tHtPt2!_y92 ӑ[B-FUhԴ‰1U s0ND"W A, ȁiSwi֙\*\q".G#Tf۵Nƙgq (M,̔rj/ U7[0`ot</3qF|yXѨd&ӡ0מ2޹T2FMǶz:-Pt 6`1簕/NYB@± s`aOe^M(|2{(3<<bܠyF}OPNFJktg[C7sKT&쮞x= W nn-oCe@+]!;¡7p&ahMIFT9єLeMx CI(m { \ˣ4SdX8NY&GxXÞcIh5vd`4Tz~Zp˱; 3l`^q+2˪Tܗ+,<p1P3OĿDN$"j`x~'1g3&ݝq r! ׭gRwb1k3B4!h>9I7eg>toƽ&WG-NJ\係^&Y"98]A.砂P*c`jd&3FIf *h5l^ .>y&Ѥj~ 32CpNFCM@f3] H s5*Sa"TAZyOy}( eе8:5reh`o-j%~9yǗX`{*K Kw,*Kk@e<溨h|Y@XjJ?-}G$T%FύDŽ Y!QN??׀'ځ^n09w'*2r-'f&(ݓ#S۵^2֧,]ΕAiGq8wDqo$ӹ!GQqhdFm[9yO Tbiגq#6\9)l<v,sЃSlv*jVIRJa^b ZEz0 _AIKMnIݺQ/HrU֏Dz(n4{,&[M\WF6w5 u +G5n kxrDQ*ڦe\)irB$ LXz'Bs%!5Kt[`폰 kIxQwl\j`uW(>ODVb_K̵{tWܠ%iԱ껳i\3OJ,}no&:`eF(ȟ PwQn3vIJz BG:vf'#s QJ3O߱Lj eF!xRxU+|afTЧrXc pyk"VݠkCAQ*S@)LUȃz; v՛vy͇xLMGr 8h'WmcQr]Yv?ֲ(zOkz;Fv|yaY;~4>'ГȖ~2!"$ ((2g ](nNSc.fJ 4V:I7w4=}DzmϷSqX՛#@#{BOhm䁊a &Pmh@CGv-:NuZTgix”<4OX]M U.80t!Vn&]5NL/xz*jqx-~m"$Ez,/_I'nDJ8ؓxBͩىNtXu-=?sr8si.};zAZ4uQα3'*[z<⺯y%Nj#JqqԵBTIWu2 >}r@n^;A|w%* =G4j|0ŝCQaZ%k]zļ79Myt_2XfI-=6سYu/ce3r1v^XÅ{JT<499tp]"Y 2v?_*t`zm(e^7OK<\#OEt@{eD8% !A3싍X]$s=&&#x؆Zr/%,ԋvcs#ĹJ2x%@kRQHA*CDML-;q<ňN!n%񷮍hVOuM06TLHo1<`zu L&0cŪTyNy_!W(qv;o䶀:#ui2mv;ei`O|ltCc\i"#$B\ݵgXh$J⮉3ro! cNBJk¿Kl2Śiobdu|ӒjT]}_ lZ.*4A !<ңp^?ќMB:b:Et(E~-<<2`>G÷իibΝVM%Ǡ1Ǜ(p:׼I/n#4ogImSNMJIff50ed}lakDC$ @~T6XtgJ^-* ődwF8ßqH(F.~wY#^[lG:Bh9F SVMc>6zQxK -n:95&w"0qqqL_*Ld}yj0＊ Qî]iRg2\nƭ͉p]wM5Q䆴c"Sp緺ZHY~LU˪ǔ$\xf]qbHtt ;&gyH14 ulW?i#2Ƥ_OBE"TlL&KT:\Ѭrqצ$?5[wZ%w7YZ$˹\ӮI H&]=a!q}UK*'wu0AOd.%F3)U=<.4AJNJ_;VI7pvJ3rYEky35AD 6 <{w6$200]˲0z_f\@Z+K7Q;Ù5B~xeidn|l6F2Rщ-d9j'fg3Y,'[~^nе'-^NnǁNbyJgzPZm7FHK@k@$Dʥ]k4yU"hhd5AXV)sn x9FQyXJJ\|L*ZVz~XMӊR:$%sy v1[1+D4wt(KʏЧ`pG(~@~w??6h઱frrk*-op~R %oG܃6g'>2B,s&hZž_)twXi8]fmYo[Sݣ`4JWJfY9ݤ~| f%ݭi˅ꆻ͡Լ|-(k^mre0]*OgGcS~9@zdZԛ3}Z.'\ké2}ul"ׇiFk+]KbNF4OqB,{'K+f X*daF[HY*<`s*` B]^؋ u}R>6cO< 0wzqSc s|bΖ3IôcXø'zH{ajESG5 QחL,7`L;c_a6aHp0{ .c`uZ{@OI'³Rǡ `-Civkyt7L] c`hrr=R{u4Jb_ڴמm؊kFoz״ ]@K*fux$@S+0`~1~Βֽ!2QYV* [hO"Z1Vy`WCMޕyUrpŁuƴ2/y "Zb%;ԝLQH_/K:A樌^fc]:j"L>O|jQZ.m+7Ы `$eUz:įO&E3:Q*MhT`۶'d<憙lQ]k9qc1t*Q(Ў]/\bꉦ3VsZ|m1Hm8_8.Y>XMy .կY٦nUDHXϡNs &>,-K-IvE噧qJ:嵸~qdWԒ`9bb'YLdUƊ\D7ȹ*HgƎml|񳦊vڎx S ܁M PڽJ<Ͼ )4]"G_¾Ld&jvNiq{̝Dka6BD,<%dCV_E FJ8 hH<=,1 Ex^g"эj=68R#4 涥-~INGpdm:,h?ė#C@n$)8X`l[-ADBэBG(@M׊pzgV5֥U"ͳvֽu)Jnj8*M<$8 3 -7<.Дu3JrӐ_X{z& ťN0,is uQXvDP*0ddq #?ڧĞPRCAeN v TV_dwĎ TG<5`%=5=n(zȯx];h xrʺf8UX׳pV ׎ל:@p`tRS?a¶籗mxeUFR/wpG1 ]m G4dԵKmn{2KN$̵ZdZjpP m"ljnG)WYƹDmtℹ4F+0_WF}~pc4WGÙFEjԡi) N~(wґ\L[$02 ЍW- 28&9.ڒZe[$+v*|ܪc-p,?td,f>gQ6&.j82I~Pr~m|OJ+N5D%c&n{T &LB@9^U~+2?T(/!C{EBa>WA#m(j2 ~7ML<&/- ֦슠/=knFWxRMN@t.sfӴӏ,}d$(` 2sgEI}1 c.1qDF}6Hd\qO#(HQ:,g2H<P^7v፪]LIAԤʣ`[U2R=b[˜|}(u}Oi7qRF#={khz=`!*RR,N٢*)t+lr,cB;AodFyj]}}3Mh> ֠tz E6 OV'T{BVUĐ% pIj &:0h׆QIiO 5N3eZRbAC}uWS " u:& WiwqP# ŝRiL˄2OJLFVv%Ϊ'&eE*[6_gYl >aIaP8V 8z-^̂ꅒRܐNaR:m\du%G魆$fr7 &C4E YM4]::Σ6W,ghZFh"C ^Ze9 v_ݔZU;ł?@i7En^x?alJ>JF>ƌLZ.Qt<7uSZt1r=XvS6=m`dv l|ŇGȇ/_'!2nMmRps:w"x:(G;GD7 -8iGjpBciqrC/S # z+Y]=9aV<ދ_n8u @: S ngVw y#-vegAlTxJlc)O|\D #g;CuSj>N`fvG0s t² Xen sXB9Q;zYdl;MהSf9RpL'\M=qJCje]s;bXˈg-n=y.J+:;j gi-˅#@%Y=:MbP_O ͢+:-(]ӂZ5{:̅̆ *l*RU!Ȕm /s͗Yn*g[6r-2%Zx!-x/۲#2m ʈ2q2~'Cse)I% 5Se{1Fé:Ҝu'L`ue9gl=ȆSFIC皑* mX)TW`hSl>/'`Ji7k%}ݑd{^f.H9*. q?YP >64,\?뙾uFZ)JRꎣ46EXGs-2_VIE ʲ8aqHd4s?\;!V/J{J4OÙެ<;5N3f$ˁ33h aj \-@Jzǁ% zkI˵) ͌\lHE36,팘"N!,WlxbݍxZːBv 5E8D6 c5:ݾtWE]iipm1SwTru™Ne ' A>\&{J[ۥJ} .Zۯ#C*<hUSs[(2}(SG?FIIX"i&Л jqwuVra[dX0O sUp$gv )s6QP"4=l?"zkkt):)(8.컛uu^ s@3cq~ <_V وf(@"AwH/h#.!0*UNP7a8=G+,Y-,:bnFzPXE 'fS 6+d%$8j+lj%'xOMU-mijHNV(eϋ?ps16Aޜ8"kˎi~iO$^;-tuUXjE8P`c4K#QA)Δ$UWf!Sf,Y-P%tda#M@8 soWGM``.=b)s s0T&^ \#+W@?1=gfxSukOD`!CB=%1ͻVq -=qQ>\ U& S9`\t@Vr~*4.tFXF~ţDΘhX_Vv?ƬXս+.1  =rǬm\ fh4U; BzلI"M\U;ܣ<V" .ηL3JNv͖ G. ܔd_Ytb}F+;2kz%_di0pZ~0Rx #$B6p"#1Ǫ$VEXq 0q*.&rN )?~~b4"hOWMG̹P:|B*rHFHuqݛr&jF" -%{> U$o nԍ%JY Gr2Շ͗dR5 }lm}&iL7X4K`rC>'R ,b6_j,84]Sf3Ls'D!4ylGxgf0{x5 "=UVoI1($*EgïQu&%<L[9:TI&ѼJќ-G+xA >-=TߥEq 𪇘"*!n6u\ NFqHBL0(jjM)VS tuL YzSuTF|! x4kp;fA@ }{Z6Z.u0LlO 4}ب'īN矋~t^Dϟwy{?:xDe?p+dmj2@-ٸW" Q:$ԟL؆t eNF)8)@Fn ]ɂwi/<x 4Nt3Ss"2`{Lzh#k:5 _k_qv1%w1EtIgdOfފc $]^^xnz g{5`L9 JgA`&|bz~S}e~6`^^B4}pCt7 1/DRl iVgߕ3@\ |#oP+"o)\|9{$^@jY/ج*э8N[wQyd;0)`S${`WtOq➒7oĨ52JYۦ޵XqT6. UAΤ638f1~YFnSQ;yL*Vqtޙ )v`ðT_~_yQaC4Ѕ7<)+: &eF"z.ēߺZj7C aP/KgLQ<D/@kP!1މo꫙@-1*0?׍Qi `}ZE"!H)%j Ze:86{sҋA-RRԟ> dkǺ5# cQ/XSJ{lZlÒgH(t;V}Vo0%>ǵHU L VRȏ"멍)j96\U;au6HxFdHVD o7 ,;s(w|D ]wʬU:q܅|=?8]d#Ow33.ce[5bh%a`ҤM$CCkAE2S̓b?ebYѢ%haOTg)[5 ɣnjV&NzN2'e|d-QY 7Z?}ᰄu4]#u)pS7 '"@I,9}t /:YX4^P j.`ʳ®kfr%BM ,*F=,&;0K4ثB yW;ّiǽ~Ux,8` f"SEt֬:im˓C]Z&?U ]ȞVBJ"cՓoV*$xD/G tK$6ȍ:fa8pB{o%:2ښ/,B*<=^O6l˧C+bivɉusZ%;Ҫ9\ҚxG~뉼7EW.r4MgvjCRe^_i3ZE'Gꀿ9LF uH:

М) =ڳ< =zTKb/E~dMy:~s\hyp6U\Н(EܰQ<#,fa2/T*)ȎXfnQ N})꼇*W74H~p0>3l_=Pd^-~v"1GLf”f;},BAG{2 ?/Q .zIAT }* C%:KNYhF.zFVګ3{~^ıF/kpfׅcԥ{FSH%0ns f^̖SdkN;ʻ%TrZ`2 R@VɼnbBC75_e`244ϦӺZ<LպD PyFQOV}i#7K 3_,el3AFn$>E $W#ݗH"Rx,ӒSx.+'ss;lqxxN.' ij m/4dT|Xnʳ k5mO)Gy[m<;cTBPt={EidҫMҢ2;")ivh@#=<v9'5͵˕҉LL(߃ a$t%s/ŚAO_*ͣ3Feu`E,K!|ӏ/bs(e_4 Ol%OlH{DUzXgƦJm}NtA odŦ!~5o[JxZowWy@΄.}?k͇m֟ &,eƁڃ4@yl@[ƲO>Rv uŝ.Mnn9Ԉ$> [Q+†O6xM,6uN4ABG(bSgJƤN#,ϓ>!a9d,'H0=}ZUqI߹EGBb+t'k@\%ہ)[ 4yG r}߀GLs7 y#EomitdQDSw /zyߕ]Gmke۩},S:䃄Jx,9Gj?[[Ti%8-Ub4$ B%$8BH7Vot:&>#|gM2f1 ہ*Do_;[1N}}=kvv <?UsُYcпh_bªY# =Hg JQcÝ0Fo> >*H~mTHDo4^~{??U豋[A>Nפk/Q[dFqqA T'F /S磖$.b!dSK}:hw!uw*XUst\֜>;l8Ѷ:bPW+Akl<0.`9"a:efӝř7$oh< ,u *"6$ֳ+3QGG7_}|H1tҍtJ(֨=O{`CN-Q̆wCO5 [Tpõ7^VeӐ!\5˻1qhLAІ>nK $Jn}F٧t0etY]~AU 1Sv9PK9 'ƙ'sYorZ-j`lQ~0T[8sͦ,QBvQUChRњ4XAl<}i ƪ@3r(b0f9xmz[lT6#gHfMf~:Z(pJs|Oم^bݞ }/᧟}#᧟#H}ϼ bK }=A\" @-mʀqwۺNqZ.tڸ (WX0I3Qg.~u~6Ab FCP1~yV؈Bby,- H;S/Z3m?J\יH_#߼w 6xt|yzX|3ᘝi[+XC0p~jGYꈒ^zϽ,_谻h?[R_v(YciSoծ5ʝIr{  Tx-̀oP-F^dK^ed0c0f|!|(/{r={2g_6IW d%E?pGm:r6" bxyzHf&LVnز[OHehxM"MUdP> 5TJ˭/M5Ǽ8 Iuk봴}gg{^=w:2f8tS[~mfüI-xN2A38ׁi6(J{I֣Mc- !T:ȭNH=Ic@D 1^!pp^[f^60БQuQDufS2P ? +[Zڹ^zfJGqA(tKߙYƫ+_:ZZ )t\t 0>)g_ϑ)/?[& Xd"5YWC:Q؜NZnzG,"ʥѫKSf2%zE:륷!P(M˷0 MyA1!EzB0=2%ozW2.kz(% 9pt&Ų1,"M͓os"˯T=sӖFÕ7y,xZ ~I\XeJz;H-Gm3MSMj4uXrX~]< Ұ*F>$(!L Xesa!gQ [¸1l'a.[ك[M.xAd8w& y,HY˨ud_f$NЫc a9e_$+P.LW c%愘 u}c㸜G 8#}h1FMpԸXU-sWFV:.WVHGo"cA)NU<}R)6PC*/Q9}w<:wk{*O:?t"r6|iNWI$ꁡ ` t"2n4=L<$q#pyMϖSnvTRdtu봩gw/}k[]'hQsO"}h pn y䘶VX_(жlGŖٖz kX `^'#Wsmqnz(06~6IOi*A:aE=I\6jD,;9pr]ؙL' wEjI"jQ-ӟi 5>h4M1E3pc1diBS\lj_/ی8  pqt~A)f@h ǁ\Fz\BVc ,)ɩS>\U[@ -X˫ݥڜՁyghDG8 >Yċ'zEI ʹdBbH?nVJj_t [`=7S\DF[S:LQ ےCvK gѨlEefyaKI B,zte|Hd'M-ugզd\6sv0֏jDt>y:}SYul}΅-tYr"40SW塽PUw n׮k}|ނpK\ | 6r .je4($[sګ_P)m5lӉYYR0ŠB[8"I<CQJCJ耵ha%ͺKhgtlF=ØgTa &\)ܐӍ'X?l].κ\ػMpL$;DcpN]1I9TGG~k>΢uygS1ܝgGļ*,?i7; b,S낊T^FS,yg8e}.eZWv.7Dڑv)5ܽߴ&AAOBaEce0tIX$SЖt]ʧX :hÉ# ƫͩt4z1^uZ_5W&a,lۘD-+k/Fkgy*izmqS |$ao3g+mm"y`S}8b tE֨1ɲ8;u| x^ZfK*# &HUGwE?_$x5'zbc1C{nBݭ H? lP,J ,c_ƻPu[TM,xcK?  C S,eܪ]nuIJ6޴AϧxaɸmdE%}x)& 'EPXZ`ei2Kq1'No )%rQ+YzӼ5z_|}9e"I#:5ey`1>[B~֘&CSB#]MfZO韟gY`ƻ4[g}b%~XV!Kkjb<ՙVJeB+yp{d)z]w]xh&W{w:q&=L'CU?%j-LOŹhc!i6׍x ׈PglJ;~$C^A6ȼ4ÚŅQNNU% ô#{^\+6z 6@;BY)!vd˦zdm/̱cSvdGXJ4}M֥ =He H ad% Ơz7 z-"ٜ߭t}Y8^O9ANb6Þ6P׾Z #+]|:}uA(܇Եor,nG@掭.AR9U!s[AwI#$5C-A:}}l3bP7@Ab9sWL6\ZT-el/v˃u:aߝ&dMnN}Y1߬iNq $Cw 7( A]а߱ZAv4d^% ⟳|KVј&iqf@0AL:G(莏&s0UeПogLsj+byvuo%~PWzmϝrʐT%YSpJ”I/mM}ɦ͡ΌtuZ8 f06g]9*D݇]d1_43>deo 2f '$jCq^e;Jcc "Jǎ5\Soes4,ګ۸FD}p[=}NO0(IRK洚|@m,]u}=V+ f*W *}5w ,ý#'Ǵ. d Q6E:KzJs%Մƥvg_%ȼJ&G8.Fq:ɧ# tf $d& 7n<'u*+J/^X]"605| 4P&8,p,gL&\i~0ow7>?}&wd:<.&"6/fyah{'Eli6tv,`g(CD$Imi ²ۭЙI菜0|p챈Օ_σE~aj)s͜&YVVpY:;:ń &!67hp~7m]%x"%J8~Q j;ͩfȬF/U(gwfuX0?ңO۸D_Fj=(Fx֬$#}-|".ԠuYT4V683~}ȉ^@Wbה99Ujꔻ{^8/c?&:6Y,['aDZK2=1Fk\S: ,ISA UNDo ރXx%I:!.0V'U|Mn&5jos.*Bjiɋ!I -nrɊd E$ƘY H?58/$a(*i`Ӧpvu r>Xe<^tm?|o:PMIt`ZgQzSiM.)U[z#I$'@5(R?8ɓݽ N(h|8l$Pl9(#mݔ>-(+mZ ˀR#DƘgASM=br4MlxEqzw 6pu[u~VV-(n"^6׍_m[<4x+U νk?DMxE1Tze}mw0wP>YAb KGisZ^vU"ݾhy.!QaKJ`8# '&bq\|:qGc0HO]: 7zZ0of2X_{]52%2/'V1Fxzɓ-)ZЍu3"c#3s'-泴,;= Vpz6-Jo ]'^gho<*Z Aq6*vOO2i6>A*LMZsΐVQhL:=]#[dy=Gʧ٦#BWW[[ yAtV1f$Ѯ ݢ8D*kl rߺ/mzMa 7msڝi5.\ԝFHrGRp_}@}T&J?/w+z8̼=3W|U̜ypl"W5²"<dmzJx0 -|-E) pؾIbRKfF0\$Jg+ Gw`“4X ;/ ƧݞY> ƚ(GJd`] 9:fq߰ⲱ}W|:-j R5Bk4*smsU(BN"pMm@ȝEҪ&̵f0VgKuE<ݬ]qe'M7|\ҹ9OΡ/gq=]^E\,9Rr_շo, ۖӑwj]n.[zO=ۢuZPѰHUVՂPu-e:9oAQ1c Clinical Research Careers: Explore the Opportunities – Cliniversity

Explore courses
Book a Demo

What is Clinical Research?

Clinical research is a branch of healthcare science that determines the safety and effectiveness of medications, devices, diagnostic products, and treatment regimens intended for human use. These studies may be used for the prevention, treatment, diagnosis, or relief of symptoms in a disease. Clinical research involves various phases and types, including:
  • Clinical Trials
  • Observational Studies
  • Epidemiological Studies
Enquire now

Career Opportunities in Clinical Research

Clinical research offers a diverse range of career paths, each with unique roles and responsibilities. Here are some key positions in the field:

Clinical Research Associate (CRA):

CRAs monitor clinical trials to ensure compliance with regulatory requirements and good clinical practice guidelines. They are crucial in ensuring the integrity and accuracy of the collected data.

Clinical Research Coordinator (CRC):

CRCs handle the day-to-day activities of clinical trials at research sites. They recruit participants, obtain informed consent, and ensure that the study protocol is followed.

Clinical Data Manager:

Responsible for managing and analyzing the data collected during clinical trials. They ensure data integrity and prepare it for analysis.

Regulatory Affairs Specialist:

Ensures that clinical trials comply with all regulatory requirements. They prepare and submit documentation to regulatory authorities.

Clinical Trial Manager:

Oversees the entire clinical trial process from planning and execution to reporting results. They ensure that trials run smoothly and on schedule.

Biostatistician:

Analyzes data from clinical trials to provide statistical support and ensure the validity of the results.

Medical Writer:

Prepares detailed clinical trial reports, regulatory submissions, and scientific articles based on clinical research findings.

Career Growth in Clinical Research

The field of clinical research offers significant potential for career growth and advancement. Here’s a typical career trajectory:

  • Entry-Level Roles
    Start as a Clinical Research Assistant or Coordinator to gain foundational experience.
  • Professional Development
    Pursue certifications such as the Certified Clinical Research Professional (CCRP) to enhance your skills and qualifications.
  • Specialization
    Focus on specific areas such as oncology, cardiology, or neurology to become an expert in a particular field.
  • Leadership Roles
    Advance to supervisory or managerial positions, overseeing teams and the conduct of clinical trials.
  • Consulting and Advisory Roles
    Offer expert guidance on clinical trial design, regulatory compliance, and data analysis.
  • Executive Positions
    Move into high-level roles such as Director or Vice President of Clinical Research, shaping the strategic direction of research programs.

Why Pursue a Career in Clinical Research?

High Demand

The need for new and improved treatments ensures a steady demand for skilled clinical research professionals.

Competitive Salaries

Clinical research roles offer attractive compensation, with potential for higher earnings as you advance in your career.

Global Opportunities

The field offers chances to work on international projects and collaborate with experts worldwide.

Continuous Learning

The dynamic nature of clinical research ensures ongoing professional development and learning.

Impactful Work

Your efforts directly contribute to the advancement of medical science and the improvement of patient care.

CONTACT US

Call & Enrol over the phone with one of our representatives
Ring at : +91 7066457703

Join Us

Here Is The Most Frequently
Asked Questions

What is clinical research?

Clinical research is a branch of healthcare science that determines the safety and effectiveness of medications, devices, diagnostic products, and treatment regimens intended for human use. It involves various types of studies, including clinical trials, observational studies, and epidemiological research, to gain insights into disease prevention, treatment, and management.

Clinical trials are conducted in four phases:

  • Phase I: Tests a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
  • Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
  • Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow it to be used safely.
  • Phase IV: Conducted after a drug or treatment has been approved for use by the FDA, these studies gather additional information on the drug’s effect in various populations and any side effects associated with long-term use.

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials that involve human participants. GCP ensures that the rights, safety, and well-being of trial participants are protected and that the clinical trial data are credible and accurate.

To ensure the integrity and accuracy of clinical trial data:

  • I adhere strictly to the study protocol and GCP guidelines.
  • I perform regular monitoring and auditing of trial processes and data.
  • I maintain detailed and accurate documentation.
  • I use electronic data capture (EDC) systems to minimize errors.
  • I conduct thorough training for all personnel involved in the trial.
  • I ensure proper source data verification (SDV) and data validation checks.

An informed consent form is a document that provides potential clinical trial participants with all necessary information about the study, including its purpose, duration, required procedures, potential risks and benefits, and their rights. It is important because it ensures that participants are fully aware of what they are agreeing to and can make an informed decision about their involvement in the trial.

In a previous trial, we faced a challenge with low participant recruitment. To resolve this, we conducted a thorough review of our recruitment strategies and identified areas for improvement. We increased our outreach efforts by collaborating with local healthcare providers and community organizations, updated our advertising materials to better communicate the benefits of participation, and held informational sessions to address potential participants’ concerns. These efforts significantly improved our recruitment numbers.

A Clinical Research Coordinator (CRC) manages the daily operations of clinical trials at research sites. Their responsibilities include:

Recruiting and screening participants.
Obtaining informed consent from participants.
Coordinating study visits and procedures.
Collecting and recording data.
Ensuring compliance with study protocols and regulatory requirements.
Communicating with investigators, sponsors, and regulatory authorities.
Maintaining accurate and up-to-date documentation.

When handling adverse events in a clinical trial:

I document the adverse event in detail, including the date, time, and circumstances.
I assess the severity and causality of the event.
I report the event to the principal investigator, sponsor, and regulatory authorities as required.
I ensure that the participant receives appropriate medical care.
I follow up with the participant to monitor the resolution of the event.
I review and update the risk management plan if necessary

A Data Safety Monitoring Board (DSMB) is an independent group of experts that monitors patient safety and treatment efficacy data while a clinical trial is ongoing. The DSMB reviews interim data to ensure participant safety and can recommend modifications to the study protocol or even halt the study if significant safety concerns arise.

Randomization in clinical trials is the process of assigning participants to different treatment groups using a random method, such as a computer-generated sequence. This process helps to eliminate selection bias, ensuring that the groups are comparable and that the results of the trial are reliable and valid. Randomization increases the likelihood that differences observed between groups are due to the intervention being tested rather than other factors.

Common regulatory documents used in clinical research include:

Investigational New Drug (IND) application: A request for authorization from the FDA to administer an investigational drug to humans.
Institutional Review Board (IRB) approval: Documentation that a study has been reviewed and approved by an IRB.
Informed Consent Form (ICF): A document detailing the study information and obtaining participant consent.
Case Report Forms (CRFs): Documents used to record data collected during the clinical trial.
Study Protocol: A document outlining the study objectives, design, methodology, statistical considerations, and organization.
Safety Reports: Documentation of adverse events and safety monitoring.

I stay updated with the latest developments and regulations in clinical research by:

Subscribing to industry journals and newsletters.
Attending professional conferences, workshops, and webinars.
Participating in continuing education courses and training programs.
Engaging with professional organizations such as the Society of Clinical Research Associates (SOCRA) and the Association of Clinical Research Professionals (ACRP).
Networking with colleagues and industry experts.
Regularly reviewing updates from regulatory authorities like the FDA and EMA.

An Investigator’s Brochure (IB) is a comprehensive document that provides detailed information about an investigational product. It includes preclinical and clinical data, safety information, pharmacology, toxicology, and guidance for investigators conducting clinical trials. The IB is essential for understanding the investigational product and ensuring the safety of trial participants.

To manage multiple tasks and deadlines in a clinical trial:

I prioritize tasks based on their urgency and importance.
I use project management tools to create detailed timelines and track progress.
I delegate tasks appropriately to team members.
I maintain clear and open communication with all stakeholders.
I regularly review and adjust plans to accommodate any changes or unexpected challenges.
I stay organized and focused to ensure timely and accurate completion of all tasks.

Blinding in clinical trials is the process of keeping study participants, investigators, or both unaware of which treatment participants are receiving. There are different types of blinding:

Single-Blind: Only the participants are unaware of the treatment assignment.
Double-Blind: Both the participants and the investigators are unaware of the treatment assignment.
Blinding is important because it helps prevent bias in the study results, ensuring that the observed effects are due to the treatment itself and not influenced by participants’ or investigators’ expectations

Admission Enquiry

Let's chat